Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Acalabrutinib in Chinese Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): 12-Month Efficacy and Safety Results from an Open-Label, Multicenter Phase 1/2 Trial

Shenmiao Yang, Haiwen Huang, Keshu Zhou, Xielan Zhao, Yanqiu Han, Lindong Li, Anna Butturini, Yujie Wang, Xiaofeng Liu, Peiqiong Lai, Jianyong Li

Blood (2023) 142 (Supplement 1): 6537.

https://doi.org/10.1182/blood-2023-173399

Published: 2023

Journal Articles

Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

Richard R. Furman, William G. Wierda, Anna Schuh, Piers EM Patten, Jorge M. Chaves, Jennifer R. Brown, Talha Munir, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, Krish Patel, Jennifer A. Woyach, Anna Butturini, Marianne de Borja, Min Hui Wang, Susan O'Brien, John C. Byrd

Blood (2022) 140 (Supplement 1): 9873–9875.

https://doi.org/10.1182/blood-2022-162394

Published: 2022

Journal Articles

Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up

John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O'Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Piers EM Patten, Talha Munir, Krish Patel, Anna Butturini, Marianne de Borja, Min Hui Wang, Nitin Jain, William G. Wierda

Blood (2022) 140 (Supplement 1): 9865–9867.

https://doi.org/10.1182/blood-2022-159542

Published: 2022

Journal Articles

Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features

Matthew S. Davids, Jeff P. Sharman, Toby A. Eyre, Jennifer A. Woyach, Paulo Andre P. de Miranda, Mina Shahkarami, Anna Butturini, Ugochinyere Emeribe, John C. Byrd

Blood (2022) 140 (Supplement 1): 4173–4175.

https://doi.org/10.1182/blood-2022-157018

Published: 2022

Journal Articles

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Jennifer A. Woyach, MD, James S. Blachly, MD, Kerry A. Rogers, MD, Seema A Bhat, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Mojgan Jianfar, MD, Gerard Lozanski, MD, David M. Weiss, Barbara L. Andersen, PhD, Priti Patel, MD, Veerendra Munugalavadla, PhD, Anna Butturini, MD, Yan Xu, Min Hui Wang, PhD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-136317

Published: 2020

Journal Articles

A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results

Ahmed Sawas, MD, Kerry J. Savage, MDMSc, Raymond Perez, MD, Ranjana H Advani, MD, Anna Butturini, MD, Jacqueline Lackey, Fabio Trave, MD, Banmeet Anand, PhD, Yao Huang, Leonard Reyno, MD, Owen A. O'Connor, MD

Blood (2015) 126 (23): 3976.

https://doi.org/10.1182/blood.V126.23.3976.3976

Published: 2015

Journal Articles

Adverse Reactions to PEG and Erwinia Asparaginase and Correlation with Anti-Asparaginase Antibody Data and Survival in Children with Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group Study CCG 1961.

Girish Dhall, M.D., Tamekia Jones, PhD, David Radvinsky, Nathan Robison, MD, Anna Butturini, MD, Joan I Rubin, RN, Paul S. Gaynon, MD, Eduard H Panosyan, MD, Ioannis A Avramis, Vassilios I Avramis, PhD, Lawrence J. Ettinger, MD, Nita L. Seibel, MD

Blood (2009) 114 (22): 3077.

https://doi.org/10.1182/blood.V114.22.3077.3077

Published: 2009

Journal Articles

Adipocytes Secrete Factors That Cause Leukemia Drug Resistance.

James W Behan, Jason P Yun, Marina P Proektor, Ehsan A Ehsanipour, Anna Butturini, MD, Nora Heisterkamp, PhD, Steven D Mittelman, MD, PhD

Blood (2008) 112 (11): 1346.

https://doi.org/10.1182/blood.V112.11.1346.1346

Published: 2008

Journal Articles

Obesity Alters the Pharmacokinetics of Vincristine in Mice.

James W Behan, Vassilios I Avramis, PhD, Jason P Yun, Anna Butturini, MD, Steven D Mittelman, MD, PhD

Blood (2008) 112 (11): 1636.

https://doi.org/10.1182/blood.V112.11.1636.1636

Published: 2008

Journal Articles

Obesity Independently Predicts Event Free Survival (EFS) in Adults with BCR-ABL-Negative Acute Lymphoblastic Leukemia (ALL). A Retrospective Analysis of Two GIMEMA Studies.

Blood (2005) 106 (11): 1828.

https://doi.org/10.1182/blood.V106.11.1828.1828

Published: 2005

Journal Articles

Down Syndrome (DS) Patients with Intermediate Risk (IR) Acute Lymphoblastic Leukemia (ALL): Events and Outcome on Children’s Cancer Group (CCG) 1891 Study.

Janet Franklin, MD, MPH, Staci Larsen, BA, Fred Dorey, PhD, Anna Butturini, MD, Cecelia Fu, MD, Beverly Lange, MD, Harland Sather, PhD, Paul Gaynon, MD

Blood (2004) 104 (11): 1958.

https://doi.org/10.1182/blood.V104.11.1958.1958

Published: 2004

Journal Articles

Obesity and Body Weight Independently Predict Relapse and Survival in Preadolescents and Teenagers with Acute Lymphoblastic Leukemia (ALL). A Retrospective Analysis of Five Children Cancer Group (CCG) Studies.

Anna Butturini, MD, Fred Dorey, PhD, Paul Gaynon, MD, Cecilia Fu, MD, Janet Franklin, MD, Stuart Siegel, MD, Nancy Sacks, RN, Nita Siebel, MD, David Henry, MD, Paul Rogers, MD, Beverly Lange, MD, Harland Sather, PhD, Michael Trigg, MD, Archie Bleyer, MD

Blood (2004) 104 (11): 992.

https://doi.org/10.1182/blood.V104.11.992.992

Published: 2004

NARROW

Acalabrutinib in Chinese Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): 12-Month Efficacy and Safety Results from an Open-Label, Multicenter Phase 1/2 Trial

Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up

Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results

Adverse Reactions to PEG and Erwinia Asparaginase and Correlation with Anti-Asparaginase Antibody Data and Survival in Children with Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group Study CCG 1961.

Adipocytes Secrete Factors That Cause Leukemia Drug Resistance.

Obesity Alters the Pharmacokinetics of Vincristine in Mice.

Obesity Independently Predicts Event Free Survival (EFS) in Adults with BCR-ABL-Negative Acute Lymphoblastic Leukemia (ALL). A Retrospective Analysis of Two GIMEMA Studies.

Down Syndrome (DS) Patients with Intermediate Risk (IR) Acute Lymphoblastic Leukemia (ALL): Events and Outcome on Children’s Cancer Group (CCG) 1891 Study.

Obesity and Body Weight Independently Predict Relapse and Survival in Preadolescents and Teenagers with Acute Lymphoblastic Leukemia (ALL). A Retrospective Analysis of Five Children Cancer Group (CCG) Studies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only